Dr. Michael A. Campos, M.D.
Critical Care Medicine (Critical Care Medicine (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 171
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Critical Care Medicine (Internal Medicine) Physician primary
FL license ME76058 -
Internal Medicine Physician
FL license ME76058 -
Pulmonary Disease Physician
FL license ME76058
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Jackson Health System Miami, FL
Medical groups
- University of Miami (2,377 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 171
- Services billed
- 377
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 121 | 74 |
| Critical care, first 30-74 minutes | 111 | 48 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 44 | 15 |
| Established patient office or other outpatient visit, 30-39 minutes | 28 | 25 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 26 | 15 |
| Established patient office or other outpatient visit, 40-54 minutes | 22 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Miami, FL | 33 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Miami, FL | 24 |
| Montelukast Sodium Other prescribers in Miami, FL | 21 |
| Fluticasone Propionate Other prescribers in Miami, FL | 19 |
| Prednisone Other prescribers in Miami, FL | 18 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Miami, FL | 16 |
| Prolastin C (alpha-1-proteinase inhibitor) | 16 |
| Glassia (alpha-1-proteinase inhibitor) | 16 |
| Azelastine Hcl Other prescribers in Miami, FL | 15 |
| Fluticasone Propionate Hfa (fluticasone propionate) Other prescribers in Miami, FL | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 7 payments worth $8,508 in total to this clinician.
| Grifols Shared Services North America, Inc. | $6,914 |
|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $1,188 |
| Genzyme Corporation | $406 |
| Consulting Fee | $8,076 |
|---|---|
| Food and Beverage | $432 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Grifols Shared Services North America, Inc. Mar 21, 2025 | Consulting Fee Prolastin-C Liquid · Pulmonology | $6,888 |
| Takeda Pharmaceuticals U.S.A., Inc. Feb 28, 2025 | Consulting Fee GLASSIA · IMMUNOLOGY | $1,188 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $9,857 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
Grifols Therapeutics LLC · Completed · NCT04722887
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.